Literature DB >> 27509181

Association between Single Nucleotide Polymorphisms in Gamma-Aminobutyric Acid B Receptor, Insulin Receptor Substrate-1, and Hypocretin Neuropeptide Precursor Genes and Susceptibility to Obstructive Sleep Apnea Hypopnea Syndrome in a Chinese Han Population.

Zhijun Li1, Tingyu Tang, Jianzong Du, Wenjuan Wu, Xiaoxi Zhou, Guangyue Qin.   

Abstract

OBJECTIVE: To investigate genotype-phenotype changes between rs29230 in γ-aminobutyric acid B receptor (GABBR1), rs1801278 in insulin receptor substrate-1 (IRS-1), and rs9902709 in hypocretin neuropeptide precursor (HCRT) and obstructive sleep apnea hypopnea syndrome (OSAHS) in Chinese Han individuals.
MATERIALS AND METHODS: A total of 130 patients with OSAHS and 136 age- and gender-matched healthy controls were enrolled in this study. A brief description of DNA extraction and genotyping is given. Multivariate unconditional logistic regression analysis adjusted for gender and age was used to estimate the associations of single nucleotide polymorphisms (SNPs) rs29230 (GABBR1), rs1801278 (IRS-1), and rs9902709 (HCRT) with OSAHS risk. Subgroup analysis was performed to evaluate differences in these SNPs among subgroups according to gender, body mass index (BMI), and severity of disease.
RESULTS: Genotype and allele frequencies of rs29230 were significantly different between cases and controls (p = 0.0205 and p = 0.0191, respectively; odds ratio = 0.493, 95% confidence interval = 0.271-0.896), especially for male patients (p = 0.0259 and p = 0.0202, respectively). Subgroup analysis according to BMI also revealed a significant allele difference for rs29230 between cases and controls in the overweight subgroup (p = 0.0333). Furthermore, allele and genotype frequencies of rs1801278 showed significant differences between cases and controls (p = 0.0488 and p = 0.0471, respectively). However, no association was observed between rs9902709 and OSAHS risk (p = 0.2762), and no differences were identified in other subgroups.
CONCLUSION: In this study, there was an association between variants of rs29230 and rs1801278 and OSAHS risk in the Chinese Han population but not for rs9902709.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27509181      PMCID: PMC5588507          DOI: 10.1159/000448997

Source DB:  PubMed          Journal:  Med Princ Pract        ISSN: 1011-7571            Impact factor:   1.927


Significance of the Study

• To investigate genotype-phenotype changes associated with SNPs of rs1801278 (GABBR1), rs29230 (IRS-1), and rs9902709 (HCRT) genes in Chinese Han individuals. This study revealed that the SNPs of rs1801278 and rs29230 were susceptible markers for the increasing risk of obstructive sleep hypoapnea syndrome, but rs9902709 did not appear to be a susceptibility locus.

Introduction

Obstructive sleep apnea hypopnea syndrome (OSAHS) is a common disorder characterized by the limitation of airflow resulting from repetitive episodes of partial or complete upper airway collapse during sleep [1]. These recurrent episodes usually lead to repetitive breathing pauses during sleep, accompanied by snoring, marked sleep fragmentation, transient hypoxia and hypercapnia, and chronic excessive daytime sleepiness [2]. While ventilation is normal in waking patients with OSAHS, sleep-related reductions in motoneuronal activity result in collapse of the upper airway. With changing lifestyles and dietary habits, the global prevalence of OSAHS has been determined to be fairly high, and is estimated to affect up to 17% of middle-aged men and 9% of middle-aged women [3]. The pathogenesis of OSAHS is not fully elucidated at the hereditary level. However, genetic and epidemiological studies indicate that OSAHS susceptibility is associated with multiple genetic, environmental, and developmental factors [4]. The pathophysiology of OSAHS may be investigated by detecting novel genetic susceptibility markers, which could lead to the development of new preventive and curative methods. Genetic variants increase the risk of OSAHS due to involvement in pathways of the upper airway anatomy, airway collapsibility, ventilation, and sleep-wake control [5]. An association between Ala20Val polymorphism and C/C variant of the GABBR1 Phe658Phe polymorphism and OSAHS had been reported in Turkish individuals [6], but not for the genotype and allele frequencies of IRS-1 rs1801278 [7]. In addition, also, an association between the C allele of the HCRT rs9902709 variation and OSAHS was reported in a Japanese population [8]. Hence based on these findings the objective of this study was to investigate genotype-phenotype changes between rs29230 in γ-aminobutyric acid B receptor (GABBR1), rs1801278 in insulin receptor substrate-1 (IRS-1), rs9902709 in hypocretin neuropeptide precursor (HCRT) and OSAHS in Chinese Han individuals.

Subjects and Methods

Subjects

A total of 130 Han patients with OSAHS (20 females and 110 males) and 136 controls (24 females and 112 males) who were examined at the Sleep Disorders Center of Zhejiang Hospital (Hangzhou, China) were enrolled in this study in southeast China (fig. 1). The subjects were divided into two subgroups based on body mass index (BMI). The patient cohort consisted of 116 overweight (BMI ≥25) and 14 normal-weight (BMI <25) individuals, while the control group comprised 92 overweight and 44 normal-weight subjects. Each of them provided a written informed consent prior to being enrolled in the study. The research was conducted in accordance with the World Medical Association Declaration of Helsinki and approved by the Ethics Committee of Zhejiang Hospital.
Fig. 1

Flowchart for subject recruitment. PSG = Polysomnography.

OSAHS Diagnosis and Exclusion Criteria

Study participants underwent diagnostic overnight polysomnography (Alice LE; Philips Respironics Inc., Murrysville, Pa., USA). The baseline examination comprised pulsoxymetry, electrophysiological signals (electroencephalography, electro-oculography, and electromyography), electrocardiography, observation of thoracic movement and the analysis of sleep stages, snoring phases, and awakening reactions. Recordings were reviewed independently by two sleep specialists (J.D. and T.T.). Apnea was defined as the continuous cessation of airflow for >10 s, and hypopnea as a ≥50% reduction in airflow for >10 s with oxygen desaturation of ≥4%. The apnea-hypopnea index (AHI) was calculated as the total number of apnea and hypopnea events per hour of sleep. Patients were grouped according to OSAHS severity as follows: mild OSAHS (AHI 5–15 events/h), moderate OSAHS (AHI 16–30 events/h), and severe OSAHS (AHI >30 events/h). The exclusion criteria were: hypothyroidism, acromegaly, micrognathia, central sleep apnea, rhinitis, nasal polyposis, tonsil hypertrophy, or cardiac insufficiency; chronic obstructive pulmonary disease or interstitial lung disease; a history of drug or alcohol abuse, and depression, and any kind of treatment for OSAHS. 129 subjects were excluded accordingly.

DNA Extraction and Genotyping

Peripheral blood samples were obtained from each participant and stored at −70°C. The DNA was isolated from human peripheral leukocytes of whole-blood samples using the AxyPrep Blood Genomic DNA Miniprep Kit (Axygen Biosciences, Union City, Calif., USA). The single nucleotide polymorphisms (SNPs) HCRT rs9902709, GABBR1 rs29230, and IRS-1 rs1801278 were amplified using the GeneAmp PCR System 9700 (ABI Co. Ltd., New York, N.Y., USA). Primers for polymerase chain reaction (PCR) and single-base extension were designed using Assay Designers software version 3.0 (Sequenom Inc., San Diego, Calif., USA) and were processed following standard protocols for iPLEX chemistry. Primers were synthesized by Sangon Biotech Shanghai Co. Ltd. (Shanghai, China; table 1).
Table 1

Oligonucleotide sequences used for genotyping

GeneSNPAllele/PrimersSequences
IRS-1rs1801278(Homo sapiens)AlleleFirst primerSecond primerExtension primerATGGGCAGACTGGGCCCTGCACCTCCC[G/A]GGG-CTGCTAGCATTTGCAGGCCTA5′-ACGTTGGATGATGGTCATGTAGTCACCCCG-3′5′-ACGTTGGATGGTCGAGATGGGCAGACTGG-3′5′-AAATGCTAGCAGCCC-3′

GABBR1rs29230(Homo sapiens)AlleleFirst primerSecond primerExtension primerATGGTTACCACATTGGGAGGAACCAG[T/C]CCTTTCGTCTGCCAGGTGAGGAGG5′-ACGTTGGATGTCGATGGTTACCACATTGGG-3′5′-ACGTTGGATGCCTGTAAGGAATTTGCCCAC-3′5′-TGGGAGGAACCAGTT-3′

HCRTrs9902709(Homo sapiens)AlleleFirst primerSecond primerExtension primerCTCTGGGATGGTGAGTCACCCCTCC[A/G]TC-CCTGGATCTTTACCTTTGTGGAA5′-ACGTTGGATGGCCAGACACCATGAACCTTC-3′5′-ACGTTGGATGTTTGCTTCTCTGGGATGGTG-3′5′-GGAAAGGTAAAGATCCAGGGA-3′
Multiplex PCR was performed in 5-μl volumes containing 0.1 units of HotStar Taq polymerase (Qiagen, Hilden, Germany), 10 ng of whole genome-amplified genomic DNA, 2.5 pmol of each primer, and 2.5 μmol of dNTP. Thermocycling was carried out at 94°C for 15 min followed by 45 cycles of 94°C for 20 s, 56°C for 30 s, and 72°C for 1 min, with a final incubation at 72°C for 3 min. Unincorporated dNTPs were deactivated using 0.3 units of shrimp alkaline phosphatase (Sequenom Inc.). Primer extension was performed using 5.4 pmol of each primer extension probe, 50 μmol of the appropriate ddNTP combination, and 0.5 units of iPLEX enzyme (Sequenom Inc.). Extension reactions were carried out at 94°C for 15 min followed by 45 cycles at 94°C for 20 s, then 56°C for 30 s, and 72°C for 1 min, and a final incubation at 72°C for 3 min. Thermocycling A cation exchange resin was used to remove residual salt from the reactions. Purified primer extension reaction products were spotted into a 384-well SpectroCHIP using the MassARRAY Nanodispenser (Sequenom Co.) and determined by a matrix-assisted laser desorption/ionization time-of-flight mass spectrometer. Genotype calling was performed in real time with MassARRAY RT software version 3.0.0.4 and analyzed using MassARRAY Typer software version 3.4.

Statistical Analysis

Continuous values were expressed as means ± standard deviation. Hardy-Weinberg equilibrium testing was carried out for all three SNPs. Pearson's χ2 tests were used to compare the alleles and genotypes between cases and controls, and stratified analyses were performed to evaluate the difference of these SNPs among subgroups based on gender, BMI, and severity of disease. Odds ratios (ORs) and 95% confidence intervals (CIs) were obtained with Plink software (OpenLink Software Inc., Burlington, Mass., USA). p values <0.05 were considered statistically significant.

Results

Characteristics of Study Subjects

Clinical and polysomnographic characteristics of study subjects are shown in table 2. The mean age was 51.78 ± 12.24 years (range = 31–67) in cases and 50.88 ± 8.21 years (range = 31–60) in controls, Following BMI classification, 116 OSAHS patients (89.23%) had a higher likelihood of being overweight, while, by contrast, 44 healthy subjects (32.35%) with normal weight were more prevalent in the control group; the difference between the two groups was significant (p = 0.005). We examined Hardy-Weinberg equilibrium in the controls and cases with observed p values of 0.00212 for rs9902709, 0.86024 for rs1801278, and 0.85051 for rs29230.
Table 2

Clinical and polysomnographic characteristics of the study subjects

VariablesPatientsControlsp value
Demographics
Gender, n0.817
 Male110 (84.6%)112 (82.4%)
 Female20 (15.4%)24 (17.6%)
Mean age ± SD, years51.78 ± 12.2450.88 ± 8.210.617
Mean BMI ± SD28.17 ± 3.6225.38 ± 3.17
Normal weight, n14 (10.77%)44 (32.35%)0.005
Overweight, n116 (89.23%)92 (67.65%)
Severity of disease, n<0.001
 Normal0136
 Mild26 (20%)UN
 Moderate22 (16.92%)UN
 Severe82 (63.08%)UN

Polysomnography (means ± SD)
AHI, events/h35.66 ± 19.523.43 ± 1.12<0.001
 Male38.78 ± 18.163.32 ± 2.05
 Female25.76 ± 15.133.12 ± 1.07
 Overweight39.12 ± 22.324.09 ± 1.87
 Normal weight28.34 ± 13.322.89 ± 0.97
MAI, events/h26.28 ± 16.094.87 ± 1.56<0.001
LSaO2, %74.27 ± 11.1596.85 ± 3.8<0.001
ODI4, events/h43.42 ± 25.174.16 ± 1.08
Sleep stages, % of TST
 NREM154.21 ± 18.7947.9 ± 20.04<0.001
 NREM299.73 ± 32.3192.1 ± 36.21<0.001
 NREM3/460.51 ± 19.9546.23 ± 15.72<0.001
 REM53.23 ± 18.3139.74 ± 16.36<0.001

LSaO2 = Lowest oxygen saturation; MAI = microarousal index; NREM = non-rapid eye movement sleep; ODI4 = oxygen desaturation index; REM = rapid eye movement sleep; SD = standard deviation; TST = total sleep time; UN = unknown.

Polymorphisms in Case and Control Cohorts

For SNP rs29230, allele and genotype frequencies were 71.7% (T), 28.3% (C), 9.3% (CC), 50.4% (TT), and 40.3% (CT) in patients, and 83.8% (T), 16.2% (C), 69.9% (TT), and 30.1% (CT) in controls; differences were significant between the two groups (χ2 = 5.4914, p = 0.0191, OR = 0.493, 95% CI = 0.271–0.896, and χ2 = 7.7729, p = 0.0205), indicating that possession of the C allele is associated with susceptibility to OSAHS (table 3). To further explore allele and genotype frequency differences, the subgroup analysis demonstrated that the allele and genotype distributions of rs29230 were 70.5% (T), 29.5% (C), 11.8% (CC), 51.8% (TT), and 36.4% (CT) in male patients, and 83.9% (T), 16.1% (C), 67.9% (TT), 32.1% (CT), and 0% (CC) in male controls, indicating that possession of at least one C allele is significantly more frequent in patients than controls (p = 0.0202, OR = 0.467, 95% CI = 0.243–0.895, and p = 0.0259; table 4). However, no differences were identified between female patients and controls (table 4). Likewise, the C allele of rs29230 was more prevalent in cases than controls in the overweight subgroup (p = 0.0333, OR = 0.487, 95% CI = 0.250–0.951; table 5).
Table 3

Allele and genotype distribution in the patients and controls

GeneCasesControlsχ2p valueOR (95% CI)
HCRT rs9902709
Allele1.18570.2762
 A255 (0.981)260 (0.942)
 G5 (0.019)16 (0.058)2.443 (0.465–12.820)
Genotype1.14080.5653
 AG5 (0.038)6 (0.044)
 AA125 (0.962)128 (0.941)
 GG0 (0.000)2 (0.015)

GABBR1 rs29230
Allele5.49140.0191
 T185 (0.717)228 (0.838)
 C73 (0.283)44 (0.162)0.493 (0.271–0.896)
Genotype7.77290.0205
 CC12 (0.093)0 (0.000)
 TT65 (0.504)95 (0.699)
 CT52 (0.403)41 (0.301)

IRS-1 rs1801278
Allele3.88190.0488
 A0 (0.000)9 (0.033)
 G260 (1.000)263 (0.967)
Genotype3.94210.0471
 AG0 (0.000)9 (0.067)
 GG130 (1.000)127 (0.933)
Table 4

Allele and genotype distribution in the patients and controls both according to gender

GeneMale
p valueOR(95% CI)Female
controlsp valueOR(95% CI)
casescontrolsc ases
HCRT rs9902709
Allele
 A215 (0.977)215 (0.960)40 (1.000)45 (0.938)
 G5 (0.023)9 (0.040)0.42062 (0.359–11.149)0 (0.000)3 (0.062)0.3558
Genotype
 AG5 (0.045)5 (0.044)0 (0.000)2 (0.083)
AA105 (0.955)105 (0.938)20 (1.000)22 (0.917)0.3501
 GG0 (0.000)2 (0.018)0.6092

GABBR1 rs29230
Allele
T155 (0.705)188 (0.839)27 (0.750)40 (0.833)
C65 (0.295)36 (0.161)0.02020.467 (0.243–0.895)9 (0.250)8 (0.167)0.6500.7 (0.149–3.282)
Genotype
 CC13 (0.118)0 (0.000)
 TT57 (0.518)76 (0.679)10 (0.556)15 (0.625)
 CT40 (0.364)36 (0.321)0.02598 (0.444)9 (0.375)0.60390.625 (0.105–3.707)

IRS-1 rs1801278
Allele
 A0 (0.000)5 (0.022)0 (0.000)3 (0.063)
 G220 (1.000)219 (0.978)0.083940 (1.000)45 (0.937)0.3558
Genotype
 AG0 (0.000)5 (0.045)0 (0.000)2 (0.083)
 GG110 (1.000)107 (0.955)0.081820 (1.000)22 (0.917)0.3501
Table 5

Allele and genotype distribution in the patients and controls according to BMI

GeneNormal weight
p valueOR(95% CI)Overweight
p valueOR(95% CI)
casescontrolscasescontrolsvalue
HCRTrs9902709
Allele
 A28 (1.000)82 (0.976)227 (0.978)175 (0.951)
 G0 (0.000)2 (0.024)0.56023.029 (0.737–12.455)5 (0.022)9 (0.049)0.26152.591 (0.464–14.47)
Genotype
 AG0 (0.000)2 (0.048)5 (0.043)5 (0.054)
 AA14 (1.000)40 (0.952)0.5566111 (0.957)85 (0.924)
 GG0 (0.000)2 (0.022)0.5116

GABBR1rs29230
Allele
 T23 (0.958)72 (0.857)165 (0.711)155 (0.842)
 C1 (0.042)12 (0.143)0.58821.833 (0.199–16.916)67 (0.289)29 (0.158)0.03330.487 (0.250–0.951)
Genotype
 TT10 (0.833)30 (0.714)58 (0.500)60 (0.652)
 CT0045 (0.388)32 (0.348)
 CC2 (0.167)12 (0.286)0.55732.000 (0.191–20.899)13 (0.112)0 (0.000)0.0506

IRS-1rs1801278
Allele
 A0 (0.000)4 (0.048)0 (0.000)4 (0.022)
 G28 (1.000)80 (0.952)0.4057232 (1.000)180 (0.978)0.1106
Genotype
 AG0 (0.000)5 (0.119)0 (0.000)4 (0.043)
 GG14 (1.000)37 (0.881)0.3968116 (1.000)88 (0.957)0.1088
For rs1801278 variants, only the G allele was detected in cases, with A and G alleles present in controls; a significant difference was observed between cases and controls (χ2 = 3.8819, p = 0.0488; table 3). Moreover, the GG genotype was significantly more common in patients than controls (χ2 = 3.9421, p = 0.0471; table 3). However, subgroup analysis according to gender, BMI and severity of disease indicated that no significant associations with OSAHS risk were identified (tables 4, 5, 6).
Table 6

Allele and genotype distribution in OSAHS according to severity of disease

GeneOSAHS
p valueOR (95% CI)OSAHS
p valueOR (95% CI)OSAHS
p valueOR (95% CI)
mildmoderatemildseveremoderatesevere
HCRTrs9902709
Allele
 A52 (1.000)44 (1.000)52 (1.000)159 (0.970)44 (1.000)159 (0.970)
 G0 (0.000)0 (0.000)0 (0.000)5 (0.030)0.42150 (0.000)5 (0.030)0.4595
Genotype
 AG0 (0.000)0 (0.000)0 (0.000)5 (0.061)0 (0.000)5 (0.061)
 AA26 (1.000)22 (1.000)26 (1.000)77 (0.939)0.417122 (1.000)77 (0.939)0.4551

GABBR1rs29230
Allele
T45 (0.865)31 (0.705)45 (0.865)105 (0.675)31 (0.705)105 (0.675)
C7 (0.135)13 (0.295)0.31232.0637 (0.135)55 (0.325)0.09242.64813 (0.295)55 (0.325)0.63981.284
(0.499–8.530)(0.827–8.478)(0.450–3.663)
Genotype
 CC2 (0.077)2 (0.091)2 (0.077)6 (0.075)2 (0.091)6 (0.075)
 TT20 (0.769)15 (0.682)20 (0.769)35 (0.438)15 (0.682)35 (0.438)
 CT4 (0.154)5 (0.227)0.70444 (0.154)39 (0.487)0.07755 (0.227)39 (0.487)0.146

IRS-1rs1801278
Allele
 G52 (1.000)44 (1.000)52 (1.000)164 (1.000)44 (1.000)164 (1.000)
Genotype
 GG26 (1.000)22 (1.000)26 (1.000)82 (1.000)22 (1.000)82 (1.000)
Allele and genotype frequencies of rs9902709 were 98.5% (A), 1.5% (G), 3.1% (AG), and 96.9% (AA) in cases, and 96.3% (A), 3.7% (G), 4.4% (AG), 94.1% (AA), and 1.5% (GG) in controls; the lack of significance between the two groups indicates that rs9902709 variants are not involved in the etiology of OSAHS (χ2 = 1.1857, p = 0.2762, OR = 2.443, 95% CI = 0.465–12.82, and χ2 = 1.1408, p = 0.5653; table 3). Furthermore, stratified analysis according to gender, BMI, and severity of disease also revealed no associations with OSAHS (tables 4, 5, 6).

Discussion

The present study showed that the SNPs GABBR1 rs29230 and IRS-1 rs1801278 were susceptibility candidates for OSAHS in Chinese Han individuals. However, no association between HCRT rs9902709 and OSAHS was revealed. The patency of the upper airway during respiration is controlled mostly by muscle activity, which also prevents collapse due to negative airway pressure [9]. Hypoglossal motoneurons are cholinergic elements that innervate tongue muscles and play important roles during respiration. Dysfunction of the hypoglossal motoneurons appears to be implicated in OSAHS [10]. The hypoglossal motor nucleus releases GABA, which has an important physiological function through its association with a large family of receptors, including the metabotropic GABAB receptor [11]. This is encoded by GABBR1, which maps to chromosome 6, contains 22 exons, and spans at least 18 kb [12,13]. It is therefore conceivable that GABBR1 variations correlate with the etiology of OSAHS. Our present study showed significant differences in GABBR1 SNP rs29230 between OSAHS cases and controls (p = 0.0205), especially in male and overweight patients, which was concordant with those reports. The previous research by Bayazit et al. [6] showed that GABBR1 polymorphisms are associated with the occurrence of OSAHS in the Turkish population. However, the overweight individuals in OSAHS patients were more prevalent than healthy controls, which may increase the possibility of obtaining spurious findings because an increased body weight can cause the development of OSAHS. Nevertheless, our findings and previous studies indicate that GABBR1 is a susceptibility locus for OSAHS, independently of ethnic background and environmental agents. Our present study also identified a strong association between the IRS-1 rs1801278 G allele or GG genotype and an increased risk of developing OSAHS in the Chinese Han population. To the best of our knowledge, the association between OSAHS and type 2 diabetes mellitus and insulin resistance is independent of obesity [14]. The IRS is the main substrate of insulin receptor tyrosine kinase, and represents a key element in the actions of insulin and insulin-like growth factor. The IRS family consists of 4 closely related members, and IRS-1 on chromosome 2q has been regarded as a plausible susceptibility locus for insulin resistance in type 2 diabetes mellitus. Among the known IRS-1 polymorphisms, associations were previously observed with diabetes mellitus, cancer, multiple myeloma, and Alzheimer's disease [15,16,17,18]. However, Bayazit et al. [6] reported no significant differences in the genotype and allele frequencies of IRS-1 rs1801278 between OSAHS patients and controls overall, but IRS-1 variants in male Turkish patients appeared to be susceptible to OSAHS development via a gender-specific comparison [7], which was inconsistent with our finding. The discrepancy between our results and the previous study could be attributed to ethnic or environmental factors, so further studies are needed to verify the findings. Additionally, the current research demonstrated that no association between rs9902709 variants and OSAHS was identified in Chinese Han individuals. Based on our results, it seems reasonable to speculate that HCRT variants are not involved in the development of OSAHS. The previous study reported that circulating hypocretin levels were significantly lower in OSAHS patients than controls, and inversely correlated with the severity of OSAHS [19,20]; however, a clinical trial by Ahmed et al. [8] had previously found that the frequency of the HCRT rs9902709 variation increased HCRT expression, and was associated with a decreased risk for OSAHS in the Japanese population. These differences between the two studies may be primarily attributed to environmental factors which have the potential to interact with the genetic background. The present study had two limitations: the sample size was relatively small and OSAHS patients were more likely to be overweight than controls, which might have increased the chance of obtaining spurious findings. Future analysis should investigate a larger sample size, and include these risk factors.

Conclusion

The present study showed that SNPs rs1801278 and rs29230 were associated with an increased risk of OSAHS, and that HCRT did not appear to be a susceptibility gene for OSAHS.

Disclosure Statement

There is no conflict of interest.
  20 in total

1.  Low plasma orexin-A levels were improved by continuous positive airway pressure treatment in patients with severe obstructive sleep apnea-hypopnea syndrome.

Authors:  Shigeru Sakurai; Tsuguo Nishijima; Susumu Takahashi; Kohei Yamauchi; Zenei Arihara; Kazuhiro Takahashi
Journal:  Chest       Date:  2005-03       Impact factor: 9.410

2.  Cotransmission of GABA and glycine to brain stem motoneurons.

Authors:  J A O'Brien; A J Berger
Journal:  J Neurophysiol       Date:  1999-09       Impact factor: 2.714

3.  The genetics of sleep apnea.

Authors:  Susan Redline; Peter V. Tishler
Journal:  Sleep Med Rev       Date:  2000-12       Impact factor: 11.609

4.  Human gamma-aminobutyric acid B receptor gene: complementary DNA cloning, expression, chromosomal location, and genomic organization.

Authors:  V L Goei; J Choi; J Ahn; C L Bowlus; R Raha-Chowdhury; J R Gruen
Journal:  Biol Psychiatry       Date:  1998-10-15       Impact factor: 13.382

5.  The occurrence of sleep-disordered breathing among middle-aged adults.

Authors:  T Young; M Palta; J Dempsey; J Skatrud; S Weber; S Badr
Journal:  N Engl J Med       Date:  1993-04-29       Impact factor: 91.245

6.  Association between insulin receptor substrate 1 Gly972Arg polymorphism and cancer risk.

Authors:  Hongtuan Zhang; Andi Wang; Hui Ma; Yong Xu
Journal:  Tumour Biol       Date:  2013-05-25

Review 7.  Muscles of the pharynx: structural and contractile properties.

Authors:  E van Lunteren
Journal:  Ear Nose Throat J       Date:  1993-01       Impact factor: 1.697

8.  Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of multiple myeloma.

Authors:  Brenda M Birmann; Rulla M Tamimi; Edward Giovannucci; Bernard Rosner; David J Hunter; Peter Kraft; Constantine Mitsiades; Kenneth C Anderson; Graham A Colditz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

9.  GABA (gamma-amino-butyric acid) neurotransmission: identification and fine mapping of the human GABAB receptor gene.

Authors:  A Grifa; A Totaro; J M Rommens; M Carella; A Roetto; L Borgato; L Zelante; P Gasparini
Journal:  Biochem Biophys Res Commun       Date:  1998-09-18       Impact factor: 3.575

10.  A whole-genome scan for obstructive sleep apnea and obesity.

Authors:  Lyle J Palmer; Sarah G Buxbaum; Emma Larkin; Sanjay R Patel; Robert C Elston; Peter V Tishler; Susan Redline
Journal:  Am J Hum Genet       Date:  2002-12-23       Impact factor: 11.025

View more
  2 in total

1.  Nutrigenetic genotyping study in relation to Sleep Apnea Clinical Score.

Authors:  K Gkouskou; I M Vlastos; D Chaniotis; A Markaki; K Choulakis; E Prokopakis
Journal:  Sleep Breath       Date:  2018-10-17       Impact factor: 2.816

2.  Characterization of genetic and phenotypic heterogeneity of obstructive sleep apnea using electronic health records.

Authors:  Olivia J Veatch; Christopher R Bauer; Brendan T Keenan; Navya S Josyula; Diego R Mazzotti; Kanika Bagai; Beth A Malow; Janet D Robishaw; Allan I Pack; Sarah A Pendergrass
Journal:  BMC Med Genomics       Date:  2020-07-25       Impact factor: 3.622

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.